Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research (AACR), April 17 – 21, 2010, in Washington, DC.
The spotlight of this year's presentations will be on pancreatic cancer, highlighted by a study correlating the results from a blood test for pancreatic cancer detection with responses to a radiolabeled antibody therapy. Additionally, the Company will introduce new antibody-drug conjugates (ADC) being studied in this cancer. (Please refer to the Company's press release at www.immunomedics.com/news_pdf/2010_PDF/PR01212010.pdf for more information on the new blood test).
Other presentations will include scientific studies on a new method for delivering small interference RNA molecules to cancer cells using the Company's patented Dock-and-Lock technology; the development of novel ADCs with camptothecin's active metabolite, called SN-38, and their application to the treatment of certain cancers; the feasibility and improved efficacy of combining radioimmunotherapy and immunochemotherapy in pancreatic cancer; the development and effects of a tetrameric RNase toxin conjugated to a humanized antibody against solid tumors with broad prevalence; and improved lymphoma cell killing with anti-HLA-DR and anti-CD74 antibodies (anti-HLA-DR antibody, IMMU-114, is being prepared for clinical testing, while the anti-CD74 antibody, milatuzumab, is completing Phase I trials).
The schedule and meeting places for the poster sessions, together with the abstract and poster board numbers, are listed below:
- "Targeted delivery of siRNAs to diverse solid cancers by a novel immunoconjugate comprising tetrameric human protamine linked to an internalizing anti-TROP-2 humanized antibody" [Abstract No. LB-34, Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 1, Sunday, April 18, 2:00 p.m. – 5:00 p.m., Poster Section 39, Exhibit Hall A-C]
- "Efficacious therapies of two human pancreatic cancer xenografts and an aggressive human lymphoma xenografts with redesigned antibody-SN-38 conjugates" [Abstract No. 2438, Session Title: Monoclonal Antibodies 1, Monday, April 19, 2:00 p.m. – 5:00 p.m., Poster Board #15, Exhibit Hall A-C]
- "Cross-linker evaluation in the design of antibody-SN-38 conjugates for cancer therapy" [Abstract No. 2439, Session Title: Monoclonal Antibodies 1, Monday, April 19, 2:00 p.m. – 5:00 p.m., Poster Board #16, Exhibit Hall A-C]
- "PAM4-antigen levels in the serum of patients with pancreatic carcinoma: Early detection of disease and correlation with responses to radioimmunotherapy" [Abstract No. 4622, Session Title: Biomarkers for Early Detection of Cancer, Tuesday, April 20, 2:00 p.m. – 5:00 p.m., Poster Board #4, Exhibit Hall A-C]
- "Sensitivity of NHL to killing by anti-HLA-DR and anti-CD74 mAbs is increased by interferon-gamma" [Abstract No. 5341, Session Title: Monoclonal Antibodies 2, Wednesday, April 21, 8:00 a.m. – 11:00 a.m., Poster Board #12, Exhibit Hall A-C]
- "Potent ribonuclease-based immunotoxins comprising quadruple ranpirnase (Rap) site-specifically conjugated to B-cell lymphoma-targeting antibodies" [Abstract No. 5345, Session Title: Monoclonal Antibodies 2, Wednesday, April 21, 8:00 a.m. – 11:00 a.m., Poster Board #16, Exhibit Hall A-C]
- "A novel immunotoxin comprising quadruple RNase tethered to an internalizing anti-TROP-2 humanized MAb shows potent cytotoxicity against diverse solid tumors in vitro" [Abstract No. 5346, Session Title: Monoclonal Antibodies 2, Wednesday, April 21, 8:00 a.m. – 11:00 a.m., Poster Board #17, Exhibit Hall A-C]
- "Combining antibody-targeted radiation (radioimmunotherapy) and antibody-SN-38 conjugates (ADC) improves pancreatic cancer therapy" [Abstract No. 5543, Session Title: Preclinical Radiotherapeutics, Wednesday, April 21, 8:00 a.m. – 11:00 a.m., Poster Board #4, Exhibit Hall A-C]
SOURCE Immunomedics, Inc.